Tumor necrosis factor and DNA topoisomerase II inhibitors in human ovarian cancer: Potential role in chemotherapy

M. G. Aluigi, D. Debernardis, G. Cimoli, C. Ottoboni, S. Parodi, P. Russo

Research output: Contribution to journalArticlepeer-review

Abstract

Seven ovarian and one cervical human cancer cell lines were examined for their sensitivity or resistance to tumor necrosis factor, to three topoisomerase II inhibitors and to cisplatin. Only one line exhibited the multidrug-resistance phenotype and another one an 'atypical'-MDR phenotype. The combination of TNF and topoisomerase-II inhibitors produced enhanced cytotoxicity and overcame the MDR and the atypical resistance. No potentiation of cisplatin cytotoxicity was observed. These findings suggest that TNF enhances the activity of DNA topoisomerase II both in TNF resistant and sensitive cells.

Original languageEnglish
Pages (from-to)461-467
Number of pages7
JournalInternational Journal of Oncology
Volume7
Issue number3
Publication statusPublished - 1995

Keywords

  • chemotherapy
  • drug-resistance
  • ovarian cancer
  • TNF
  • topoisomerase II

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Tumor necrosis factor and DNA topoisomerase II inhibitors in human ovarian cancer: Potential role in chemotherapy'. Together they form a unique fingerprint.

Cite this